Shield Therapeutics Secures $10 Million Funding and Expands Share Capital

Shield Therapeutics ( (GB:STX) ) has issued an announcement.

Shield Therapeutics announced that all resolutions were passed at their General Meeting, enabling the company to raise $10 million through a Subscription and securing a Panel Waiver. Additionally, a RetailBook Offer raised £96,715.83. The company will issue 259,634,117 new Ordinary Shares, with trading on AIM expected to begin on 30 December 2024. This financial infusion is poised to bolster Shield’s operations and enhance its market positioning, particularly as it continues to expand the reach of its flagship product, ACCRUFeR®, in various international markets.

More about Shield Therapeutics

Shield Therapeutics plc is a commercial stage specialty pharmaceutical company focused on delivering ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative oral therapy for iron deficiency and iron deficiency anemia. The company addresses a significant unmet medical need for patients suffering from these conditions. Shield has launched ACCRUFeR® in the U.S. through an exclusive collaboration with Viatris and has licensed rights to commercialize the product in other regions, including Europe, China, and Canada. The product is protected by patents until the mid-2030s.

YTD Price Performance: -58.96%

Average Trading Volume: 2,691,811

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: £21.51M

For an in-depth examination of STX stock, go to TipRanks’ Stock Analysis page.